Trial · NCT00000136
Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
NCT00000136, Phase 3, Completed, Johns Hopkins Bloomberg School of Public Health; results first posted 2015-10-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT). Trials, record NCT00000136. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00000136
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
- NCT number
- NCT00000136
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 234 participants, actual
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Conditions
- HIV Infections, Cytomegalovirus Retinitis
- Interventions
- Foscarnet, Ganciclovir
- First posted
- 1999-09-24
- Last updated
- 2015-10-22
- Results first posted
- 2015-10-22
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality | All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mortality | All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mortality | Foscarnet | 107 | participants | ||
| Mortality | Ganciclovir | 127 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Foscarnet | 107 | |
| Overall Study | STARTED | Ganciclovir | 127 | |
| Overall Study | COMPLETED | Foscarnet | 107 | |
| Overall Study | COMPLETED | Ganciclovir | 127 | |
| Overall Study | NOT COMPLETED | Foscarnet | 0 | |
| Overall Study | NOT COMPLETED | Ganciclovir | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Opportunistic Infection | Immune system disorders | Foscarnet | 60 | 107 | 153 |
| serious | Opportunistic Infection | Immune system disorders | Ganciclovir | 73 | 127 | 180 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Foscarnet | ||
| Total, all-cause mortality | Ganciclovir | ||
| Total, other adverse events | Foscarnet | 0 | 107 |
| Total, other adverse events | Ganciclovir | 0 | 127 |
| Total, serious adverse events | Foscarnet | 60 | 107 |
| Total, serious adverse events | Ganciclovir | 73 | 127 |
Source ClinicalTrials.gov
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10EY008057 | Studies of Ocular Complications of AIDS - Coordinating Center | VAN NATTA, MARK L | JOHNS HOPKINS UNIVERSITY | NATIONAL EYE INSTITUTE | 1988 to 2012 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Foscarnet vs Ganciclovir: Mortality | Trial comparisons |
| Foscarnet vs Ganciclovir: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00000136
GET https://conductscience.org/api/trials/v1/NCT00000136/registered